{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:45:22Z","timestamp":1792439122471,"version":"4.5.0"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Cancer registries and hospital electronic medical records are commonly used to investigate drug repurposing candidates for cancer. However, administrative data are often more accessible than data from cancer registries and medical records. Therefore, we evaluated if administrative data could be used to evaluate drug repurposing for cancer by conducting an example study on the association between beta-blocker use and breast cancer mortality.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A retrospective cohort study of women aged \u226550\u00a0years with incident breast cancer was conducted using a linked dataset with statewide hospital admission data and nationwide medication claims data. Women receiving beta blockers and first-line anti-hypertensives prior to and at diagnosis were compared. Breast cancer molecular subtypes and metastasis status were inferred by algorithms from commonly prescribed breast cancer antineoplastics and hospitalization diagnosis codes, respectively. Subdistribution hazard ratios (sHR) and corresponding 95% confidence intervals (CIs) for breast cancer mortality were estimated using Fine and Gray\u2019s competing risk models adjusted for age, Charlson comorbidity index, congestive heart failure, myocardial infraction, molecular subtype, presence of metastasis at diagnosis, and breast cancer surgery.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> 2,758 women were hospitalized for incident breast cancer. 604 received beta-blockers and 1,387 received first-line antihypertensives. In total, 154 breast cancer deaths were identified over a median follow-up time of 2.7\u00a0years. We found no significant association between use of any beta-blocker and breast-cancer mortality (sHR 0.86, 95%CI 0.58\u20131.28), or when stratified by beta-blocker type (non-selective, sHR 0.42, 95%CI 0.14\u20131.25; selective, sHR 0.95, 95%CI 0.63\u20131.43). Results were not significant when stratified by molecular subtypes (e.g., triple negative breast cancer (TNBC), any beta blocker, sHR 0.16, 95%CI 0.02\u20131.51).<\/jats:p><jats:p><jats:bold>Discussion:<\/jats:bold> It is possible to use administrative data to explore drug repurposing opportunities. Although non-significant, an indication of an association was found for the TNBC subtype, which aligns with previous studies using registry data. Future studies with larger sample size, longer follow-up are required to confirm the association, and linkage to clinical data sources are required to validate our methodologies.<\/jats:p>","DOI":"10.3389\/fphar.2023.1227330","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T16:14:54Z","timestamp":1691684094000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Using administrative healthcare data to evaluate drug repurposing opportunities for cancer: the possibility of using beta-blockers to treat breast cancer"],"prefix":"10.3389","volume":"14","author":[{"given":"George S. Q.","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Botteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica K.","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenni","family":"Ilom\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"key":"B2","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/GO.21.00065","article-title":"Cancer registration in the Middle East, north africa, and Turkey: scope and challenges","volume":"7","author":"Abdul-Sater","year":"2021","journal-title":"JCO Glob. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/pds.5547","article-title":"Core concepts in pharmacoepidemiology: key biases arising in pharmacoepidemiologic studies","volume":"32","author":"Acton","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B4","volume-title":"Australian classification of Health Interventions (ACHI)","year":"2019"},{"key":"B5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1200\/EDBK_159069","article-title":"Challenges in treating premenopausal women with endocrine-sensitive breast cancer","volume":"35","author":"Azim","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1200\/JCO.2010.33.5422","article-title":"Beta blockers and breast cancer mortality: a population-based study","volume":"29","author":"Barron","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"107886","DOI":"10.1016\/j.intimp.2021.107886","article-title":"Breast cancer immunotherapy: current and novel approaches","volume":"98","author":"Barzaman","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"B8","volume-title":"Therapeutic guidelines (eTG)","year":"2021"},{"key":"B9","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10549-013-2654-3","article-title":"Therapeutic effect of beta-blockers in triple-negative breast cancer postmenopausal women","volume":"140","author":"Botteri","year":"2013","journal-title":"Breast Cancer Res. Treat"},{"key":"B10","doi-asserted-by":"publisher","first-page":"100066","DOI":"10.1016\/j.esmoop.2021.100066","article-title":"Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis","volume":"6","author":"Caparica","year":"2021","journal-title":"ESMO Open"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1093\/ije\/dyt196","article-title":"Beta-blocker usage and breast cancer survival: a nested case-control study within a UK clinical practice research datalink cohort","volume":"42","author":"Cardwell","year":"2013","journal-title":"Int. J. Epidemiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13058-016-0782-5","article-title":"Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts","volume":"18","author":"Cardwell","year":"2016","journal-title":"Breast Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"eadf1147","DOI":"10.1126\/scitranslmed.adf1147","article-title":"Beta-blockade enhances anthracycline control of metastasis in triple-negative breast cancer","volume":"15","author":"Chang","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.bbi.2016.06.011","article-title":"\u03b22-Adrenoceptors on tumor cells play a critical role in stress-enhanced metastasis in a mouse model of breast cancer","volume":"57","author":"Chang","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"B15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1002\/ijc.31980","article-title":"New use for old drugs: the protective effect of atypical antipsychotics on hepatocellular carcinoma","volume":"144","author":"Chen","year":"2019","journal-title":"Int. J. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.3390\/cancers12061560","article-title":"New use for old drugs: the protective effect of risperidone on colorectal cancer","volume":"12","author":"Chen","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.drudis.2020.12.013","article-title":"Applications of artificial intelligence in drug development using real-world data","volume":"26","author":"Chen","year":"2021","journal-title":"Drug Discov. Today"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.3892\/or.2016.4710","article-title":"Inhibition of \u03b22-adrenergic receptor reduces triple-negative breast cancer brain metastases: the potential benefit of perioperative \u03b2-blockade","volume":"35","author":"Choy","year":"2016","journal-title":"Oncol. Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","article-title":"Molecular pathways: beta-adrenergic signaling in cancer","volume":"18","author":"Cole","year":"2012","journal-title":"Clin. Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"101579","DOI":"10.1016\/j.canep.2019.101579","article-title":"Beta-blocker use and mortality following ovarian cancer diagnosis: a population-based study","volume":"62","author":"Couttenier","year":"2019","journal-title":"Cancer Epidemiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13058-015-0655-3","article-title":"\u03b22-adrenoceptor signaling regulates invadopodia formation to enhance tumor cell invasion","volume":"17","author":"Creed","year":"2015","journal-title":"Breast Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.mayocp.2013.09.001","article-title":"Effect of beta-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death","volume":"88","author":"De Giorgi","year":"2013","journal-title":"Mayo Clin. Proc"},{"key":"B24","unstructured":"eviQ (cancer Institute NSW). Cancer Institute NSW"},{"key":"B25","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J. Am. Stat. Assoc"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s41388-021-02170-0","article-title":"Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment","volume":"41","author":"Fjaestad","year":"2022","journal-title":"Oncogene"},{"key":"B27","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/cpt.2185","article-title":"Real-world evidence for assessing pharmaceutical treatments in the context of COVID-19","volume":"109","author":"Franklin","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10549-011-1505-3","article-title":"Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort","volume":"129","author":"Ganz","year":"2011","journal-title":"Breast Cancer Res. Treat"},{"key":"B29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejca.2021.01.029","article-title":"Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients","volume":"147","author":"Gillis","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1158\/1078-0432.CCR-19-2641","article-title":"Preoperative beta-blockade with propranolol reduces biomarkers of metastasis in breast cancer: a phase II randomized trial","volume":"26","author":"Hiller","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/YCO.0000000000000579","article-title":"Using clinical registries, administrative data and electronic medical records to improve medication safety and effectiveness in dementia. Curr Opin Psychiatry","volume":"33","author":"Ilomaki","year":"2020","journal-title":"Mar"},{"key":"B32","volume-title":"Immunomodulators and antineoplastics.","year":"2021"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/cncr.28546","article-title":"Stage-specific associations between beta blocker use and prognosis after colorectal cancer","volume":"120","author":"Jansen","year":"2014"},{"key":"B34","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s10549-011-1662-4","article-title":"The effect of delays in treatment for breast cancer metastasis on survival","volume":"130","author":"Jung","year":"2011","journal-title":"Breast Cancer Res. Treat"},{"key":"B35","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/JMDH.S160029","article-title":"Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making","volume":"11","author":"Katkade","year":"2018","journal-title":"J. Multidiscip. Healthc."},{"key":"B36","doi-asserted-by":"publisher","first-page":"10634","DOI":"10.1038\/ncomms10634","article-title":"Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination","volume":"7","author":"Le","year":"2016","journal-title":"Nat. Commun"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41416-022-01891-7","article-title":"\u03b2-Blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis","volume":"127","author":"Lofling","year":"2022","journal-title":"Br. J. cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"985","DOI":"10.2147\/OTT.S78836","article-title":"Impact of beta-blockers on prostate cancer mortality: a meta-analysis of 16,825 patients","volume":"8","author":"Lu","year":"2015","journal-title":"Onco Targets Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr. Epidemiol. Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.3390\/ijerph19094959","article-title":"Health statistics in Australia: what we know and do not know","volume":"19","author":"Madden","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1236361","DOI":"10.1126\/science.1236361","article-title":"Autonomic nerve development contributes to prostate cancer progression","volume":"341","author":"Magnon","year":"2013","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1021\/acsomega.2c05821","article-title":"Drug repurposing: a new hope in drug discovery for prostate cancer","volume":"8","author":"Malik","year":"2023","journal-title":"ACS Omega"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1200\/JCO.2010.33.4441","article-title":"Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer","volume":"29","author":"Melhem-Bertrandt","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1186\/s13104-015-1616-8","article-title":"The Australian pharmaceutical benefits Scheme data collection: a practical guide for researchers","volume":"8","author":"Mellish","year":"2015","journal-title":"BMC Res. Notes"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3389\/fonc.2020.01130","article-title":"The influence of pre-existing beta-blockers use on survival outcomes in HER2 positive advanced breast cancer: pooled analysis of clinical trial data","volume":"10","author":"Modi","year":"20202020","journal-title":"Front. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.22034\/APJCP.2017.18.8.2027","article-title":"Systematic review of hospital based cancer registries (HBCRs): necessary tool to improve quality of care in cancer patients","volume":"18","author":"Mohammadzadeh","year":"2017","journal-title":"Asian Pac J. Cancer Prev."},{"key":"B1","volume-title":"105 Multiple causes of death: An analysis of all natural and selected chronic disease causes of death 1997-2007","year":"2012"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.3390\/cancers13143588","article-title":"Repurposing DPP-4 inhibitors for colorectal cancer: a retrospective and single center study","volume":"13","author":"Ng","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2188\/jea.JE20160180","article-title":"Critical points for interpreting patients' survival rate using cancer registries: a literature review","volume":"28","author":"Okuyama","year":"2018","journal-title":"J. Epidemiol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/jamiaopen\/ooaa048","article-title":"Framework for identifying drug repurposing candidates from observational healthcare data","volume":"3","author":"Ozery-Flato","year":"2020","journal-title":"JAMIA Open"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1002\/ijc.21723","article-title":"The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB\/c nude mice is inhibited by beta-blockers","volume":"118","author":"Palm","year":"2006","journal-title":"Int. J. Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.3802\/jgo.2021.32.e65","article-title":"Impact of metformin on survival outcome in ovarian cancer: a nationwide population-based cohort study","volume":"32","author":"Park","year":"2021","journal-title":"J. Gynecol. Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"Drug repurposing: a promising tool to accelerate the drug discovery process","volume":"24","author":"Parvathaneni","year":"2019","journal-title":"Drug Discov. Today"},{"key":"B53","doi-asserted-by":"publisher","first-page":"797","DOI":"10.18632\/oncotarget.343","article-title":"Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment","volume":"2","author":"Pasquier","year":"2011","journal-title":"Oncotarget"},{"key":"B54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15386\/cjmed-1015","article-title":"The role of medical registries, potential applications and limitations","volume":"92","author":"Pop","year":"2019","journal-title":"Med. Pharm. Rep"},{"key":"B55","doi-asserted-by":"publisher","first-page":"628","DOI":"10.18632\/oncotarget.101009","article-title":"Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival","volume":"1","author":"Powe","year":"2010","journal-title":"Oncotarget"},{"key":"B56","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med. Care"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/bjc.2015.133","article-title":"Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage","volume":"112","author":"Reeder","year":"2015","journal-title":"Br. J. cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/2589977513666210211163711","article-title":"Drug repurposing: an emerging tool for drug reuse, recycling and discovery","volume":"13","author":"Roy","year":"2021","journal-title":"Curr. Drug Res. Rev."},{"key":"B60","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1159\/000371871","article-title":"\u03b2-Blocker use and risk of recurrence in patients with early breast cancer","volume":"60","author":"Sakellakis","year":"2014","journal-title":"Chemotherapy"},{"key":"B61","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1158\/1078-0432.CCR-17-0152","article-title":"Perioperative COX-2 and beta-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a phase-II randomized trial","volume":"23","author":"Shaashua","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"7042","DOI":"10.1158\/0008-5472.CAN-10-0522","article-title":"The sympathetic nervous system induces a metastatic switch in primary breast cancer","volume":"70","author":"Sloan","year":"2010","journal-title":"Cancer Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1200\/JCO.2012.43.9190","article-title":"Use of beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study","volume":"31","author":"Sorensen","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"963","DOI":"10.4149\/neo_2019_190110N34","article-title":"Evidence of beta-blockers drug repurposing for the treatment of triple negative breast cancer: a systematic review","volume":"66","author":"Spini","year":"2019","journal-title":"Neoplasma"},{"key":"B65","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am. J. Epidemiol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"103422","DOI":"10.1016\/j.drudis.2022.103422","article-title":"Drug repurposing using real-world data","volume":"28","author":"Tan","year":"2023","journal-title":"Drug Discov. Today"},{"key":"B67","doi-asserted-by":"publisher","first-page":"7272","DOI":"10.18632\/oncotarget.23729","article-title":"Competing risks and cancer-specific mortality: why it matters","volume":"9","author":"Tan","year":"2018","journal-title":"Oncotarget"},{"key":"B68","volume-title":"The international statistical classification of diseases and related Health Problems, Tenth revision, Australian modification (ICD-10-AM)","year":"2019"},{"key":"B69","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1470-2045(08)70028-7","article-title":"Cancer registration in developing countries: luxury or necessity?","volume":"9","author":"Valsecchi","year":"2008","journal-title":"Lancet Oncol"},{"key":"B70","volume-title":"Victorian cancer quality index technical appendix","year":"2018"},{"key":"B71","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1002\/cncr.29392","article-title":"Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer","volume":"121","author":"Watkins","year":"2015","journal-title":"Cancer"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2016.04.004","article-title":"Beta blockers and cancer prognosis - the role of immortal time bias: a systematic review and meta-analysis","volume":"47","author":"Weberpals","year":"2016","journal-title":"Cancer Treat. Rev"},{"key":"B73","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrc1670","article-title":"Breast cancer metastasis: markers and models","volume":"5","author":"Weigelt","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"B74","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"B75","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/cpt.1769","article-title":"Electronic health records for drug repurposing: current status, challenges, and future directions","volume":"107","author":"Xu","year":"2020","journal-title":"Clin. Pharmacol. Ther"},{"key":"B76","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bja.2018.03.024","article-title":"Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies","volume":"121","author":"Yap","year":"2018","journal-title":"Br. J. Anaesth."},{"key":"B77","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1700\/950.10393","article-title":"Using administrative data to identify and stage breast cancer cases: implications for assessing quality of care","volume":"97","author":"Yuen","year":"2011","journal-title":"Tumori"},{"key":"B78","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/CEJ.0000000000000192","article-title":"\u03b2-Blocker use and mortality in cancer patients: systematic review and meta-analysis of observational studies","volume":"25","author":"Zhong","year":"2016","journal-title":"Eur. J. Cancer Prev"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1227330\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T16:15:05Z","timestamp":1691684105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1227330\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":78,"alternative-id":["10.3389\/fphar.2023.1227330"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1227330","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]},"article-number":"1227330"}}